Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is Macfarlane sitting with Ms Stevens, right? It looks like Summer in the segments. This could be from, say, February? About the time the 12 week data was(first) being compiled? The company knows this piece is coming, and uses the opportunity to delay release until more concrete analysis is performed to support the hype? I think so!
"The details relating to pharmacokinetics and pharmacodynamics are being fully analyzed so that there can be no doubt as to the cause-effect relationship of the 12-week efficacy data and this must be completed before it can be released."
Anyone know the dates of Macfarlane's sabbatical? Here is more video from that time and his involvement with the SBRT:
http://www.dementiaconference.com/people/stephen-macfarlane?A=WebApp&CCID=14420&Page=2&Items=2
http://dtsc.com.au/2016/03/30/severe-behaviour-response-teams-sbrts-referral-pathways/
The devil says it is all prequel material, because the data will show a drop in SS and the response of how the trial is not powered for that will be accompanied by the claims of relevant anecdotal proof, toward the continued rationalization of a P3.
If one were to have taken the 1558 buys as a hint, they would be doing well. That also makes it 5 for 5 on the hint speculation results. Missling batting 1000!
Huck it down boys! (I need shares ) My boy also got the 6.42s so he's back on the bid.
GLTA
§
They're almost 2 minutes behind reporting to the tape. This is going to blow up!
§
What would really be Asinine is the CEO of any company posting to a public message board. Shame on you...get a job.
§
Hopefully Papa Troll will be too busy with his sideshow to pee in our cornflakes.
http://www.thestreet.com/story/13542139/1/an-investors-guide-to-sarepta-s-eteplirsen-fda-advisory-panel-meeting.html
Also an example of how we wouldn't be near the first to have patients step up and say, "I'm telling you doc, I'm cured!"
"Sarepta closed Friday at $14.95 per share. The stock could soar to $60 on a positive panel outcome or get cut in half if the votes are negative. I'm guessing, so don't hold me those price targets, but trading is sure to be volatile in one direction or the other."
I won't hold you be 'literate either AF...
§
The newscaster said, "It's just one of many promising results..."
That sounds good. It would have been nice if they included more of the patient's interview. She said something about "putting it out of her mind", as if she tried to continue painting but the symptoms overtook. I can see how, in a larger controlled population, that this type of response would absolutely be considered clinical evidence of efficacy. It will blow the ACDS-ADL score off the chart.
3 years total data for this P2a? I think Missling is a mastermind and the very purpose of this "meaningless, low power, insignificant cohort trial" is so that the efficacy data will become so overpowering as to effect the P3, which we don't want to waste a bunch of poor BP's money on.
Thanks for dishing out the goods as usual, George!
§
A real nail-biter here!
The angel on one shoulder says the data is great and being withheld because the ducks aren't in a row...extensive PK/PD blood work is being done at the behest of a suitor...negotiations are taking place that require silence...the P3 design needs more time and is to be announced concurrent with the 12 week data...etc, etc, etc.
The devil is poking the other ear with his trident shouting the data is bad and no biotech withholds good data, only bad...YOU IDIOT!!!
Much rather be turning the lights out with my first love than facing this, but unfortunately I am...
BDITG!!!
§
More drivel. Let's just see 6 again.
I hope it was the ability she regained and not just the desire. Yes exciting...kinda like your first time in the sack. Ugh!
§
60,000 posts and we're down to maple syrup! Give us the goods Dr!
Good Sunday all...
§
Dextromethorphan and maple syrup for me!
Coconut oil whenever possible in the diet. Coconut-crusted shrimp cooked in coconut oil with maple-orange marmalade on a select salad....Manna!
Free your mind and your bod will follow.
§
Precisely!
"we no longer have a license to sell this product."
Thanks for the info...and welcome!
(Peeps coming out of the woodwork now...nice! )
bebopagogo: Looks like R&D, Bio-techne, Tocris all related. I don't know enough to ballyhoo, just think that watching research compound availability is one of the clues to partnerships. I'll assume I'm wrong and go search the pair updates...
§
Well perhaps the CGMP has changed. It still looks to me like it's unavailable. I remember TEVA's drug being reported as such right before it's partnership with Rexhann(?).
They both list Fisher Scientific as distributor:
https://www.usbio.net/distributors/USA
https://www.tocris.com/distributors.php?ItemId=290#.VxwDB3oyM7U
And a search of Fisher's site lists R&D Systems and...:
https://www.fishersci.com/shop/products/anavex-2-73-10-mg/505810
"This item has been discontinued by the manufacturer and is no longer available. Please call customer service for assistance:..."
Check! You're move.
§
No, Tocris is the CGMP provider to all other dist. See this dist site says "5058 discontinued"? That one will too, shortly.
https://www.rndsystems.com/products/anavex-2-73_5058
§
Prana is also Melbourne-based. Upping the ante in Macfarlane's potential COI. The study was poorly designed, and a comparison with our P2a reveals a clearer path to confirmation and the ability to fund and conduct a powerful P3.
Prana is currently offering DR for PBT2 in AD and it's Huntington's Disease indication is held-up by FDA pending neurotoxoligy studies to clear an acceptable dosage.
MPACs are a different ballpark than our s1 agonists.
NEWS FLASH!!!
Anavex 2-73 is NO LONGER AVAILABLE FROM TOCRIS BIOSCIENCE!!!!
https://www.tocris.com/404.php#.Vxv7BXoyM7V
This means the compound is either scrapped from development or licensed for it. Which do you think?
§
1 in 10 people age 85 and older are diagnosed with dementia. If there was a treatment effective across the spectrum of dementia indications approved by 2020 the income potential by 2025 would be more like $12B - $15B/year.
http://www.asha.org/PRPSpecificTopic.aspx?folderid=8589935289§ion=Incidence_and_Prevalence
http://qz.com/666743/dementia-rates-are-falling-dramatically-but-only-for-one-gender/
At a paltry P/E of 25 a company with a 100MM O/S would have a valuation of $3000/sh.
THAT'S WHAT I'M TALKING ABOUT!!!
Miss Australia: I swear to George that I envisioned yesterday you writing a post about your relative doing well, and then mentioning another participant in the area and their apparent progress...crazy! Thanks for posting!
§
The effect would be reported as Psychiatric Disorders. Dosage at 20 - 50mg probably would not produce grade 3 effect. Knocking back 4 pills would probably get the party started though. The safety of the prescribed dosage would not be a concern, but the potential for abuse still might be.
From the CTAD presentation:
GRADE
1(mild) 2(Moderate) 3(Severe) Total N=Events
Psychiatric disorders 6(75%) 2(25%) 0(0%) 8(8%)
How about Malcolm Baker? Where is he at?
"Anavex 2-73 has been trialled in the lab, on animals and on healthy volunteers, but this month it was administered to the first patient with the disease. Melbourne man Malcolm Baker, 73, is part of the trial, where every patient gets the active drug, and he hopes it will improve his long-term outcome."
§
Increased ability/desire in artisic and creative pursuance is common in AD sufferers. Recent links led to several publications discussing it.
“It has improved her out of all sight. She is laughing and bubbly, she has absolutely blossomed since she has been on these tablets,” he said. “Nobody can believe the difference in Valerie before the trials and now. It is a different person.”
Most Sigma receptor modulators produce euphoric and, er...bubbly effects.
Sigma Receptor
(ligands)
s (1, 2)
Agonists
3-MeO-PCE 3-MeO-PCP 3-PPP 4-MeO-PCP 4 (the 'Foxies')-IBP 4-PPBP Afobazole Alazocine Amantadine Amitriptyline Arketamine BD-1008 BD1031 BD1052 Berberine Buprenorphine Captodiame Citalopram Clorgiline Cocaine Cutamesine Cyclazocine DHEA DHEA-S Desipramine Dextrallorphan Dextromethorphan Dextrorphan Dimemorfan DMT Donepezil DTG Escitalopram Fluoxetine Fluvoxamine Heroin Ibogaine Igmesine Imipramine JO-1784 Ketamine L-687,384 Lamotrigine Lu 28-179 MDMA Memantine Metaphit Methamphetamine Methoxetamine Methylphenidate Morphine Naluzotan Noscapine OPC-14523 Opipramol PB-28 PD-144,415 Pentazocine Pentoxyverine Phencyclidine (PCP) PRE-084 Pregnenolone Pregnenolone sulfate Quetiapine RTI-55 SA-4503 Siramesine Tapentadol Tenocyclidine Tramadol UMB23 UMB82 Venlafaxine
Antagonists
AC927 AHD1 AZ66 BD1008 BD1047 BD1060 BD1063 BD1067 BMY-14802 CM156 E-5842 Haloperidol Lamotrigine LR132 LR172 MIN-101 MS-377 Naloxone Naltrexone NE-100 Panamesine PD-144418 Progesterone Rimcazole S1RA (E-52862) Sertraline SM-21 SR-31742A UMB100 UMB101 UMB103 UMB116 YZ-011 YZ-069 YZ-185
Unknown/unsorted
4C-T-2 5-MeO-DiPT 18-MC ß-Endopsychosin Chlorpromazine Clemastine Clocapramine Cloperastine D-Deprenyl DiPT DPT Gevotroline Nepinalone Selegiline TMA; Allosteric modulators: SKF-83959
A2-73 may be subject to a 'Potential For Abuse' Black Box Warning. And the patients may just end up demented manics. That would not appease the FDA. We must make certain that functional and cognitive improvements accompany the euphoric effects.
While I ended up faulting Dr Macfarlane for his past misplaced exuberances, I feel his experience and the related desire to be testing a more upstream compound led him to accept the LI role for A2-73.
Still, the 'Aussie Pump' does have it's suspicions. Yes, let's let the data speak.
§
No, it could not. But this unfounded lampoon might be wrong too:
"The stock was the subject of another round of heavy promotion in 2009–2010, in this 2009 presentation Anavex claimed once again to have a diversified pipeline of drugs under development and to potentially generate $6 billion of yearly revenues by 2020(yes billions…)
None of this ever came to pass..."
Except, it's not 2020 yet, JF!
Alzheimer’s disease breakthrough: Melbourne drug trial achieves amazing results
PATIENTS have woken up from some of the most devastating impacts of Alzheimer’s disease, regaining the ability to play sport, paint and enjoy time with family, after a world-first drug trial in Melbourne.
The remarkable results have fuelled hopes among doctors of the first major improvement in treating the horror disease since the 1990s.
Pianist Pauline Stevens has regained the ability to play the piano after being placed on the experimental Anavex 2-73 drug trial at Caulfield Hospital.
Award-winning artist Valerie Lynch has also rediscovered the ability to paint after beginning the medication, stunning her doctors, family and friends.
When Melbourne was selected as the first city in the world to test Anavex a year ago, lead researcher Associate Professor Steve Macfarlane had no idea how much of an impact it would make.
“They seem to be significantly improved in terms of what they can do. It is function that has improved and in many cases mood as well,” Prof Macfarlane said.
“To me, seeing real improvements to patients is much more important than seeing a statistically significant improvement on a rating scale.
“Seeing people regaining abilities is far more powerful and important than that.”
While the turnaround in the abilities and mood of the 32 patients involved has been the most overwhelming factor, the early data has been equally impressive. It shows a huge improvement in the cognitive ability of the patients, with the drug so far proving to be four-times more effective than the current treatment.
The drug is designed to target the sigma-1 receptor cells that remove abnormal proteins from cells, but which can stop functioning effectively as people age.
By rebooting the process, the drug is hoped to clear the build-up of troublesome proteins believed responsible for neurodegenerative conditions.
Protocols for a much larger controlled trial to begin early next year are now being drawn up as the full results of the trial led by the Caulfield Hospital, but also involving patients from the Austin, Royal Melbourne and St Vincent’s hospitals, are finalised.
After 55 years of playing the piano, Ms Stevens lost the ability to play three years ago, and was soon after diagnosed with Alzheimer’s disease.
Pauline Stevens, 78, has regained the ability to play the piano after taking a revolutionary new drug for Alzheimer's. Picture: David Caird.
Eight months ago she began having a daily pill of Anavex and it is now impossible to wipe the smile from her face as she jokes and plays the piano for her family. “I feel as though I can go and do things now that I couldn’t do. I am happy,” Ms Stevens, 78, said.
“I love playing, I love to sit down and play like I used to.”
Wiping away tears of joy as he listens, husband Tom Stevens said the turnaround has been remarkable.
“Pauline laughs at my jokes again. I have her back,” he said.
“We are at the beginning, but there is hope now where there wasn’t.”
Ms Lynch, 76, has not only picked up her paintbrushes again, but is preparing for an exhibition spanning the last 50 years of her work despite being diagnosed with Alzheimer’s in November 2014.
“People used to say that I had forgotten things or that I had already told them something, and I just said I had a lot to remember and couldn’t remember everything,” Ms Lynch said.
“Everything is better around me. I feel quite well.”
Ms Lynch’s carer Keith Everitt can recall her “going downhill fast” as she stopped painting and had difficulty around her home before joining the trial.
“It has improved her out of all sight. She is laughing and bubbly, she has absolutely blossomed since she has been on these tablets,” he said. “Nobody can believe the difference in Valerie before the trials and now. It is a different person.”
For further information on the Anavex trial, contact adclinicaltrials@cgmc.org.au or visit alfredhealth.org.au.
http://www.heraldsun.com.au/news/alzheimers-disease-breakthrough-melbourne-drug-trial-achieves-amazing-results/news-story/d96671bc643b16d2694e85e0639fea3d
§
Excellent info. Thank you!
"Although present therapy for Alzheimer disease involves enhancers of cholinergic function, disease-modifying agents may be available in the future. Emphasis is being placed on detecting the presymptomatic phase of the disease, which can be termed mild cognitive impairment (MCI)."
P300 and neuropsychological assessment in mild cognitive impairment and Alzheimer dementia.
§
One of our prime topics?
Just razzin' tom...looked like a rally starting. Your TA is spot-on, in between our 'catalyst-driven' price moves.
GLTA
§
Look up at the screen tom...got an hour left§
Yes, TauRx is using whole brain mass changes and cerebrospinal fluid analysis as biomarkers in it's trial. We could expect the same in a P3 for A2-73. Anavex is actively involved in assisting Neuronetrix in establishing the P300 ERP response as a valid early detection biomarker. The failing of plaque-clearing methodology has led mainstream science to conclude that early detection and treatment is the best route to care. Anavex's compounds are targeted at upstream, pre-symptomatic processes.
https://clinicaltrials.gov/ct2/show/NCT01689246?term=trx-&rank=1
§
ed- That TauRx study is complete and set to release results soon, as well. TauRx plans to IPO on top of their trial(s) results. It will be interesting to see what valuation they get vs what AVXL sits at at the time. This may figure into Missling's plans heavily, which could be another reason we wait longer than expected.
Woah! Was that just 535sh @ 5.35 right when you posted at 12:35??? I'm lighting some incense!
§
Except no forms filed. But somebody's buying! We shall see.
Waiting for that 150% gap up that never fills
§
hessmessinc was on the mark. Say, at least $100K so far?
Did you get your answer?
Little Orphan Anavex and the Big Bad Market
"We doubt that there’s a company more hated than Anavex Life Sciences Corp (NASDAQ:AVXL) trading on the NASDAQ. Countless negative articles, tweets, and irrational pessimism has plagued the company since the beginning. Granted the company did start as a reverse merger and did not go the traditional IPO route, but the company has been committed to Alzheimer’s research and the science behind the company is real. It seems more are rooting for the company to fail than succeed and we find this astonishing."
http://www.insiderfinancial.com/anavex-life-sciences-corp-nasdaqavxl-defies-the-bears/115200/
The market loves it's money. It likes it's big, fat IPOs that provide instant returns for dumping overpriced securities on the sheeple. It does not like retail holding 20% of the float with an iron fist....no no no!
A rundown of our Board Of Directors provides the scenario:
Anavex BOD:
Christopher U. Missling M.S., Ph.D., M.B.A. - Executive Director
Dr. Christopher U. Missling, also known as the Chris, MS, Ph.D., MBA. has been the Chief Executive Officer and President of Anavex Life Sciences Corp. since July 05, 2013 and served as its Chief Financial Officer, Secretary and Treasurer since July 05, 2013. Dr. Missling serves as the Chief Financial Officer of SEE ALGAE Technology GmbH. Dr. Missling is a Partner of New York based investment bank Brimberg & Co and has over 15 years of finance experience. He is an Investment Banker at Deutsche Bank, serving companies across various industries. Dr. Missling served as Senior Vice President of Finance, Treasurer and Secretary of Asahi Kasei Pharma America Corporation (Previously known as Artisan Pharma, Inc.) Dr. Missling has extensive financial management, operational and strategic experience in the biotechnology and pharmaceutical industries. Dr. Missling served as the Chief Financial Officer of ImmunoGen Inc., from October 25, 2004 to January 2005 and also served as its Vice President of Finance and Treasurer. He also served as Chief Financial Officer, Senior Vice President of Finance, Treasurer and Secretary of Curis, Inc. from August 2002 to November 2003 and Senior Vice President of Strategic Analysis and Planning from November 2003. Dr. Missling served as Chief Financial Officer of Axaron Bioscience AG from November 2001 to August 2002. From October 2001 to January 2002, Dr. Missling served as Head of Financial Planning of Aventis SA, with responsibility for financial modeling and determining investment valuations. From July 1997 to December 1999, he served as Head of Financial Planning at Hoechst AG. Dr. Missling was with Deutsche Bank in corporate finance and investment banking serving pharmaceutical, biotech, and diagnostic companies. He served as an Analyst in the pharmaceutical /healthcare investment banking group of Deutsche Morgan Grenfell. He serves as a Member of Scientific Advisory Board at Anavex Life Sciences Corp. Dr. Missling serves as the Chairman at Anavex Life Sciences Corp. and has been its Director since July 5, 2013. Dr. Missling received his MBA from the Kellogg Graduate School of Management at WHU and Northwestern University, with a focus on partnership valuations in the Biotechnology and Pharmaceutical industries, and his Ph.D., in Chemistry, summa cum laude, and MSc from Ludwig-Maximilians-University in Munich.
*The Chris? We call him ze Terminator!
Athanasios "Tom" Skarpelos - Founding Director
Mr. Athanasios Skarpelos, also known as Tom, founded Anavex Life Sciences. Mr. Skarpelos served as a Consultant to Anavex Life Sciences since August 2, 2010. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos is a self-employed investor with 17 years of experience and worked with private and public companies. For 10 years, he focused on biotechnology companies involved in drug discovery and drug development projects. Mr. Skarpelos has been a Director of Anavex Life Sciences Corp. since January 9, 2013.
*Not much info is available about Mr Skarpelos. He founded the company and formed it with Harvey Lalach in 2006. Now Harvey Lalach is well known in Canadian penny stock land. He was involved with Assure Energy, Globalenetcare, First Cypress Technologies and InstaPay Systems. He is where the penny stock scam implication comes from. He also sits on the BOD of La Jolla LJPC where George Tidmarsh, a former Anavex Director, is CEO. Anavex and Mr lalach parted ways in 2012. It looks like he may still hold ~140KK:
http://www.sec.gov/cgi-bin/browse-edgar?CIK=0001360545&action=getcompany
I believe the meeting of Uncle Tom Skarpelos and Dr Vamvakides is what initiated the pipeline and company and it is the Greek connection. Associations in Canada will always be with us and will be used to discredit the company. Nothing new for the Canadian connection!
Elliot Favus M.D. - Independent Director
Dr. Elliot Favus, M.D is the Founder of Favus Institutional Research, LLC and serves as its Chief Executive Officer. Dr. Favus serves as a Business Advisor of Science House Capital. He has an expertise in Healthcare Equity Research. He has been Healthcare Equity Research Analyst at Wall Street since 2006, at Lazard Capital Markets and Och-Ziff Capital Management Group. Prior to working on Wall Street, Dr. Favus was an Instructor in Medicine at Mount Sinai School of Medicine in New York. Since 2004, he is board-certified in Internal Medicine. He has been an Independent Director of Anavex Life Sciences Corp. since May 07, 2014. Dr. Favus has 10 years of basic science laboratory experience, working on human genetics projects at Harvard Medical School, The University of Chicago, and the University of Pittsburgh. Dr. Favus completed the NYU-Bellevue Hospital Internal Medicine Residency Program in 2004, and earned an M.D. from the University of Chicago Pritzker School of Medicine in 2001, and a B.A. from The University of Michigan in 1996.
*Dr Favus runs a well respected Institutional Research Provider (IRP) firm, Favus Institutional Research. His reports leaked by squakboxes like AF have had much impact on biotech stocks. His board membership is a huge plus for Anavex and a sign of validity.
Bernd Metzner Ph.D. - Independent Director
Dr. Bernd Metzner, PhD, has been the Chief Financial Officer of Ströer SE (formerly known as Ströer Media AG) since June 16, 2014 and has been its Member of Management Board since June 2014. Dr. Metzner serves as Chief Financial Officer of the Doehler Group. Dr. Metzner served as a Member of the Executive Board at Döhler GmbH. Dr. Metzner served as the Chief Administrator and member of the Board of Management at Bayer Schering Pharma AG. Dr. Metzner held worldwide financial responsibility for the Bayer Pharma Group. In his almost 10-years with Bayer AG, Dr. Metzner held several senior international management positions in the corporate finance organization of Bayer AG, including Chief Financial Officer of Bayer S.p.A. Italy and heading the coordination of the successful spin-off of Lanxess. Dr. Metzner started his career at the law firm Flick Gocke Schaumburg. Dr. Metzner served as Head of Finance - Bayer Italy. Mr. Metzner served as Member of the Board of Management of Bayer Schering Pharma AG since October 1, 2008. He has been an Independent Director of Anavex Life Sciences Corp. since May 7, 2014. He studied business administration at the University of Siegen and, after obtaining his doctorate, he became a chartered accountant.
*Now check Dr Metzner's board affiliations:
http://www.bloomberg.com/research/stocks/people/relationship.asp?personId=47097392
He is now vested with AVXL stock otions. Missling and Metzner...the German connection, and why I believe our Suitor has always been Bayer AG.
Steffen Thomas Ph.D. - Independent Director
Dr. Steffen Thomas, Ph.D. has been a Director of Anavex Life Sciences Corp. since June 2015. Dr. Thomas has over 15 years of experience as a European patent attorney and is currently practicing at Epping Hermann Fischer, a major intellectual property law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas’ legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich.
*Our German patent litigation specialist. The IP is in good hands.
It is easy to see why Wall St is afraid of the little redhead...she just might be for real!
"You love money and power and capitalism? You know they’re never going to love you back…" -Annie
§
Convince me, man!
Did he tell you these Sigma-1 receptor ligands fall into a category of substances...some of which are considered the most dangerous and illicit of street drugs?
https://en.wikipedia.org/wiki/Sigma_receptor
Did he tell you that the FDA is prepared to let a pharmaceutically-acceptable controlled preparation(s) based on this substance class penetrate the CNSD market in response to overwhelmingly positive scientific research as to the potential benefit of these substances?
I marked the this post's title for easy reference next year. See you then when you go tell it on the mountain.
§
Don't worry Scott...Moses will come talk to you soon. (rolls eyes)§
It contributed to the design of a succesful open, adaptive P2. The safety and tolerability of A2-73 will now be assessed over a 3 year period. All recent posts give answers as to why PK/PD blood work might be so critical and take this extra time before the cognitive and functional 12 week results are disclosed.
Baseline biomarker analysis is crucial to the design of a well-powered P3. The P1 established a tolerability threshold in healthy males. The P2 measures that threshold against a time-dose response curve in patients.
If the treatment has demonstrated a stabilization of the response curve, we will have a breakthrough. We may be slightly above that curve which would indicate disease modification. Much work would need to be done before that proposal could be introduced to the medical community. Our P3 will be decisively pivotal in the shortest span of time possible.
We are considering phase trials in Rett Syndrome, Epilepsy and Multiple Sclerosis. The safety data from this P2 is crucial to the design of those programs. We have a CEO who is capable of steering this company to success in a most shareholder-friendly manner. He holds 2.5% to prove it.
Thanks to all the great posts!
http://investorshub.advfn.com/boards/most_read.aspx?p=c
It still looks good to me.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117194301
§
If/when Dr Favus is no longer an independent director, he might issue a report on Anavex.
http://favusinstitutionalresearch.com/
Favus is an IRP for Instinet, fwiw.
“Instinet’s sophisticated trading platform and agency-only model make it a natural partner for us,” added Dr. Favus. “I am eager to combine our research product with Instinet's sales and trading capabilities.”
http://www.thestreet.com/story/11019151/1/instinet-adds-favus-institutional-research-as-exclusive-irp-partner.html
DSIDWY
§
Mark A. Smith, Ph.D., FRCPath was a preeminent researcher. At the time of his unfortunate death (hit by a car) in 2010 he was an adviser to Anavex on A2-73's apparent effect on Soluble Oligomers within mitochondria.
http://www.anavex.com/wp-content/uploads/9A9B8DB2.pdf
http://www.case.edu/med/pathology/faculty/smith.html
http://www.researcherid.com/ProfileView.action?returnCode=ROUTER.Unauthorized&queryString=KG0UuZjN5Wmgu8pvTYBecO4Ps0i2HRooe9mp4hZLk8U%253D&SrcApp=CR&Init=Yes
TauRx's drug LMTX(a reformed Methylene Blue)acts on Aß Oligomers:
http://www.jbc.org/content/286/5/3209.full
I believe A2-73 is a class III small molecule. If you have access, this one is a great read:
http://www.nature.com/nrm/journal/v8/n2/execsumm/nrm2101.html
This article leads from that to A3-7's importance as a dimer activist and that is why we have Christopher Missling, Anavex and the pipeline together as they are today.
§
Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73 for Alzheimer's Disease
NEW YORK, NEW YORK--(Marketwired - Oct. 22, 2013) - Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) today announced that the current issue of the peer-reviewed scientific journal PLOS ONE explains that sigma-1 receptor (Sig-1R) activity is involved in cellular survival by regulating and stabilizing a key cell stress sensor. These findings may explain the therapeutic efficacy of Sig-1R agonists like ANAVEX 2-73 in Alzheimer's disease and other neurodegenerative disorders.
According to the published report, when cells are under endoplasmic reticulum (ER) stress, the key ER stress sensor 'IRE1' induces the upregulation of critical signaling for survival and thus prevents IRE1 from triggering apoptosis (cell death). These results indicate a cellular protective action of Sig-1Rs, which could make a difference preventing cell degeneration as observed in Alzheimer's disease.
The study authors conclude that the Sig-1R molecular chaperone enhances its association with IRE1 to correct or stabilize the conformation of IRE1 when cells are facing ER stress. Without Sig-1Rs, the authors find IRE1 is vulnerable to proteasomal degradation eventually triggering apoptosis.
"When ER stress is caused by accumulation of misfolded proteins in the cell, the unfolded protein response (UPR) is triggered as a cellular stress response. The aim of these responses is to remove the accumulated protein load while preventing any further addition to the stress, so that normal function of the ER can be restored as soon as possible," said Tangui Maurice, PhD, CNRS Research Director, Head of Team 2 'Endogenous Neuroprotection in Neurodegenerative Diseases', at the University of Montpellier and INSERM. "However, in conditions of prolonged stress, when the level of unfolded proteins exceeds a threshold, the cell might commit suicide by activating the cell death pathways and the goal of the UPR changes from being one that promotes cellular survival to one that commits the cell to a pathway of apoptosis. In contrast, sustained activation of the IRE1 pathway constitutively promotes survival against ER stress."
"The sustenance of the IRE1 stability through Sig-1R might promote critically needed cellular survival and this represents an important advance in our understanding of the potential mechanisms by which our mixed Sig-1R and muscarinic drug candidate ANAVEX 2-73 might exert its neuroprotective effects," said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. "Recently, we have seen that ANAVEX 2-73 shows anti-amnesic and neuroprotective potential against amyloid-beta toxicity, and reduces mitochondrial oxidative stress, cellular loss and memory deficits in models of Alzheimer's disease. In this regard, it is interesting to note that these reported preclinical studies describing the potential therapeutic efficacies of ANAVEX 2-73 in ameliorating amyloid-beta-induced neurodegeneration might be putatively explained by this new report through its Sig-1R activity."
The report, entitled "Sigma-1 Receptor Chaperone at the ER-Mitochondrion Interface Mediates the Mitochondrion-ER-Nucleus Signaling for Cellular Survival," was performed by Dr. Tsung-Ping Su and his colleagues at the laboratory of the Cellular Pathobiology Section, Intramural Research Program/NIDA/NIH/DHHS, Baltimore, Maryland.
-------------------------------
ER stress, Mitochondrial protection and Diabetes:
http://www.anavex.com/?news=anavex-reports-that-antidepressant-fluvoxamine-reduces-stress-through-sigma-1-receptor
http://www.anavex.com/wp-content/uploads/9A9B8DB2.pdf
Is Alzheimer’s Type 3 Diabetes?
§
You were spot-on about the trial extension and it's implications.
Yes! I believe gene mutations that encode the secretion of abnormal proteins may be mediated by selective S-1/Mx ligands.
I believe Solanezumab will fail to gain approval and A2-73 will become a breakthrough AD therapy with an unprecedented off-label prescription rate. The FDA knows this too and has required the company to make long-term safety a critical component of it's compound's evaluation.
Our P2a is about to become a model for the 'wonders of the placebo effect'!
And our main event this year happens on home turf!
https://www.alz.org/aaic/abstracts/abstr-dev-topics.asp
§
Could bicyclic heterocyclic spiro compounds block cryptic exons, thereby preventing the creation of abnormal proteins which are the root cause of all neurodegenerative diseases?
Hmmm? Anybody...anybody...George?
http://www.ncbi.nlm.nih.gov/books/NBK1497/
https://www.sciencedaily.com/releases/2015/08/150806144553.htm
http://www.livescience.com/26940-dementia-proteins-found.html
https://health-innovations.org/2015/08/07/researchers-identify-the-mechanism-of-protein-clumps-in-the-brain-of-patients-with-als/
http://elifesciences.org/content/2/e00476v1
"Fascinating!"
§
"The data isn't looking so good...sooo, let's extend the trial to 3 years."
Yes, I'm sure that's exactly how it went.
§